Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its January 28, 2026 annou
2026-02-04 8:00 AM EST | Izotropic Corporation
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK. Defence will showcase its proprietary Accum® platform, a breakthrough intracellular delivery technology d
Biotechnology, Pharmaceuticals, Health
2026-02-04 3:15 AM EST | Defence Therapeutics Inc.
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-03 5:30 PM EST | Medexus Pharmaceuticals Inc.
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant. "Since 2006, the first question I have
Biotechnology, Pharmaceuticals, Health
2026-02-03 8:55 AM EST | Hemostemix Inc.
Glow Lifetech Announces Expansion into Manitoba Market and Portfolio Expansion in New Brunswick, Advancing National Growth Strategy
Toronto, Ontario--(Newsfile Corp. - February 3, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the expansion of its MOD™ and .decimal™ brands into Manitoba, alongside an expansion of its product portfolio in New Brunswick. These developments represent another step forward in the Company's national expansion strategy and build on the strong commercial momentum established in 2025. Expanding N
2026-02-03 7:30 AM EST | Glow Lifetech Corp.
Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review
New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today announced the publication of an observational case report documenting late-onset hair regrowth and related physical observations in a 49-year-old male subject, Muhammad Qasim. The published case report presents a structured, non-clinical record compiled over an extended observation period. The documentation includes longitudinal v
2026-02-03 4:43 AM EST | Case Reports in Regrowth
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury sha
Healthcare and Hospitals, Health
2026-02-03 1:10 AM EST | Cosmo Pharmaceuticals N.V.
Adia Nutrition Inc. Announces Dr. Brian Browning as Lead Physician for All Orthopedic Treatments and Specialties at Adia Med
Winter Park, Florida--(Newsfile Corp. - February 2, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, is pleased to announce that Dr. Brian L. Browning, DO, a board-certified expert in family medicine and neuromusculoskeletal medicine, is now the lead physician in charge of all orthopedic treatments and specialties at Adia Med.
Healthcare and Hospitals, Health
2026-02-02 9:00 AM EST | Adia Nutrition Inc.
Kirkman(R) Unveils Revolutionary L Reuteri: a Brain-Protective Probiotic with Immune Benefits
Lake Oswego, Oregon--(Newsfile Corp. - February 2, 2026) - Functional Brands Inc. (NASDAQ: MEHA), parent company of Kirkman®, a trusted leader in high-quality dietary supplements, today announced the launch of Kirkman® L. Reuteri PLUS, a next-generation probiotic formulated to support gut health, immune function, and gut-brain communication during pregnancy. Pregnancy represents a critical window for both maternal well-being and fetal development. Growing scientific evi
Household / Consumer / Cosmetics, Health
2026-02-02 8:00 AM EST | Functional Brands Inc.
TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered into a strategic media partnership with Dr. Phil and Envoy Media, providing access to an audience of over 19 million monthly viewers which marks a significant step in acc
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-02 3:00 AM EST | TempraMed Technologies Ltd.
Promino Announces Closing of Private Placement
Burlington, Ontario--(Newsfile Corp. - January 30, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") is pleased to announce that, further to its press releases dated December 18, 2025 and January 19, 2026, the Company has closed its private placement, issuing a total of 37,380,433 units ("Units") at a price of $0.03 per Unit for gross proceeds of $1,121,413 (the "Private Placement"). Each Unit consist
Food / Beverages, Sports, Health
2026-01-30 7:42 PM EST | Promino Nutritional Sciences, Inc.
NuGen Medical Devices Inc. Announces CFO Transition
Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, announces that Veronique Laberge has resigned from her position as Chief Financial Officer and Corporate Secretary. Her resignation is effective January 31, 2026. The Company has appointed Mr. Ajay Mishra as Chief Financial Officer and Corporate Secretary, effective January 31, 2026. Mr. M
Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-30 5:15 PM EST | NuGen Medical Devices Inc.
Edison Issues Report on Picton Property Income (PCTN)
London, United Kingdom--(Newsfile Corp. - January 30, 2026) - Edison issues report on Picton Property Income (LSE: PCTN) Picton Property Income (PCTN) has published its Q326 trading update. NAV per share increased by 0.9% to 102.4p, the sixth successive quarterly increase, driven by like-for-like property valuation gains and retained earnings. Including DPS paid, the NAV total return was 1.8%, building on the 3.4% return in H126. Q1 DPS was 1.12x covered. Operationally, PCTN is focused
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-01-30 10:17 AM EST | Edison Group
Delivra Health Brands Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health", "Delivra" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce the appointment today of John Barrett as a director of the board of directors of the Company (the "Board"). Mr. Barrett was previously a senior executive with Frito Lay an
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2026-01-30 7:25 AM EST | Delivra Health Brands Inc.
HPN Holdings, Inc. Announces Closing of the Acquisition of Orange Auto Insurance
Chicago, Illinois--(Newsfile Corp. - January 29, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or the "Company") today announced the successful closing of its acquisition of Orange Auto Insurance ("Orange"), a technology-driven nonstandard automobile insurance holding company and its managing general agency (Orange Underwriters, LLC). Orange will operate as a wholly owned subsidiary of HPN. The combined operating companies will continue to trade on the OTCIQ Market under the ticker symbol
2026-01-29 8:15 AM EST | HPN Holdings, Inc.
Adia Nutrition Announces Documentary Featuring WWE/TNA Superstar Elias/Elijah Jeff Sciullo's Recovery with Adia Med's AdiaVita Stem Cell Treatment
Winter Park, Florida--(Newsfile Corp. - January 28, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in regenerative therapies, is proud to announce an upcoming documentary chronicling the recovery of professional wrestler Jeff Sciullo—known to fans as Elias in WWE and Elijah in TNA—from a tricep injury sustained in June 2025. The film will focus on his treatment with Adia Med's AdiaVita, a high-potency stem cell product delivering over
Healthcare and Hospitals, Health
2026-01-28 10:00 AM EST | Adia Nutrition Inc.
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on th
Biotechnology, Pharmaceuticals, Health
2026-01-28 8:40 AM EST | Defence Therapeutics Inc.
Hear At Last Holdings Inc (HRAL) and GG&C Collaborate to Present New Housing Model to Jamaican Government
Miami, Florida--(Newsfile Corp. - January 28, 2026) - Hear At Last (OTCID: HRAL) on January 27/26 in collaboration with GG&C, is proud to announce the successful delivery of a comprehensive housing model for presentation to the Jamaican Government. This innovative model is designed to provide a framework for addressing the nation's housing needs and will enable key decision-makers to determine the best path forward for future housing development initiatives. The housing model presen
Household / Consumer / Cosmetics, Health
2026-01-28 8:00 AM EST | Hear AtLast Holdings, Inc
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement fina
2026-01-28 8:00 AM EST | Izotropic Corporation
Scryb Reports Fiscal 2025 Results; Strengthened Balance Sheet and Significant Cybeats Exposure
Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal year ended September 30, 2025 ("FY2025"). The filings are available on SEDAR+. Fiscal 2025 marked a transformative year for Scryb, highlighted by a materially strengthened balance sheet, significantly reduced operating costs, and a
Biotechnology, Healthcare and Hospitals, Health
2026-01-28 7:03 AM EST | Scryb Inc.